Industry news, page-1613

When discussing potential big pharma buyers for RAC, there's been little discussion about our local BP CSL.

Known mostly for for its blood products, CSL has stated in recent years its desire to expand beyond its blood products range.

Yesterday CSL announced the failure of a P3 trial of its CSL112 drug to prevent heart attacks. Their research pipeline is thinning out after another trail of a covid drug a couple of years ago.



https://12ft.io/https://www.copyright link/companies/healthcare-and-fitness/csl-suffers-setback-in-second-heart-attack-drug-trial-20240212-p5f440

And CSL is big enough to pitch for RAC, as shown by its recent $AUD 16.6bill acquisition Swiss pharma Vifor and current $147b market cap.

CSL make not look like a perfect fit for RAC, but I hope Pete is atleast talking to them ....